Pharmacological Therapies: Practice Questions & Explanations

Warfarin is monitored using PT/INR. Therapeutic INR ranges: 2.0-3.0 for most conditions (atrial fibrillation, DVT, PE, after major heart valve surgery); 2.5-3.5 for mechanical heart valves and recurrent thromboembolism. INR above 3.0-3.5 (depending on indication) increases bleeding risk; below the therapeutic range provides inadequate anticoagulation. PTT (or aPTT) monitors heparin and is targeted at 1.5-2.5 times the control. Antidotes: vitamin K reverses warfarin (slowly, hours to days); protamine sulfate reverses heparin (rapidly). Warfarin teaching: consistent intake of vitamin K-containing foods (green leafy vegetables — eat consistent amounts rather than avoiding); avoid alcohol; report unusual bleeding (gums, urine, stool); many drug interactions (especially antibiotics, NSAIDs, amiodarone) — coordinate all medications with prescriber. Direct oral anticoagulants (DOACs like apixaban, rivaroxaban) don't require routine INR monitoring.

Digoxin is a cardiac glycoside used for atrial fibrillation and heart failure. It slows heart rate (negative chronotropy) and increases contractility (positive inotropy). The nurse counts the apical heart rate for a FULL minute before administration. Hold and notify the provider if apical HR is below 60 bpm in adults (below 70 in children, below 90 in infants). Digoxin has a narrow therapeutic range (therapeutic level 0.5-2.0 ng/mL); toxicity occurs at higher levels. Signs of digoxin toxicity: anorexia, nausea, vomiting, visual disturbances (yellow-green halos around lights, blurred vision), arrhythmias including bradycardia, confusion, fatigue. Hypokalemia increases digoxin toxicity risk — monitor potassium especially in clients also taking diuretics. Antidote: digoxin immune Fab (Digibind). NCLEX commonly tests both the pre-administration check and toxicity symptoms.

Respiratory depression is the most serious adverse effect of opioids. A respiratory rate below 12 in adults warrants attention; below 10 is concerning; below 8 is critical. Priority actions: (1) Hold further opioid doses; (2) Stimulate the client (call name, gentle shake) and encourage deep breathing; (3) Assess oxygen saturation, level of consciousness, pupil size (opioids cause miosis), other vital signs; (4) Reposition for airway patency; (5) Have naloxone (Narcan) ready and administer if criteria met: 0.04-0.1 mg IV titrated to effect (full dose 0.4-2 mg if severe); (6) Provide oxygen and ventilation support as needed; (7) Notify provider. Naloxone administration: titrate to restore adequate respirations without precipitating withdrawal pain. Naloxone has a shorter half-life than most opioids, so repeat doses or infusion may be needed. After naloxone, the client may experience severe pain (the reason for the original opioid) — manage with non-opioid alternatives initially and resume opioids cautiously once safe.

Long-term exogenous corticosteroids suppress the hypothalamic-pituitary-adrenal (HPA) axis. After about 2-3 weeks of suppressive doses, the adrenal glands stop producing endogenous cortisol. Abrupt discontinuation can cause acute adrenal insufficiency (Addisonian crisis): severe weakness, hypotension, shock, hypoglycemia, hyperkalemia, life-threatening — requires emergency IV cortisol replacement. To prevent this, corticosteroids are tapered gradually over weeks to months, allowing the HPA axis to recover. Other key teaching: (1) Take with food to reduce GI upset; (2) Monitor for hyperglycemia, especially with pre-existing diabetes; (3) Long-term effects include osteoporosis (calcium and vitamin D recommended, sometimes bisphosphonates), cataracts and glaucoma, weight gain, mood changes, immunosuppression (avoid sick contacts); (4) Avoid live vaccines while immunosuppressed; (5) Report signs of infection promptly (corticosteroids mask classic signs); (6) Monitor blood pressure and weight. Stress-dose steroids may be needed during illness or surgery.

Metformin is the first-line oral medication for type 2 diabetes. Mechanism: decreases hepatic glucose production, increases peripheral insulin sensitivity. Key teaching points: (1) Take with meals to minimize GI side effects (nausea, diarrhea, abdominal discomfort — often improve over weeks); (2) Hold for 48 hours before and after iodinated contrast studies due to risk of lactic acidosis — restart only after kidney function is reassessed and confirmed stable; (3) Hold during acute illness, dehydration, surgery (situations that increase lactic acidosis risk); (4) Does NOT cause hypoglycemia when used alone (unlike sulfonylureas and insulin) because it doesn't increase insulin secretion; (5) Symptoms of lactic acidosis (rare but life-threatening): malaise, muscle pain, respiratory distress, abdominal pain, hypothermia — rare but serious complication; (6) Risk factors for lactic acidosis: renal impairment (most important), heart failure, liver disease, alcoholism, advanced age, contrast dye exposure; (7) Avoid excessive alcohol use; (8) Vitamin B12 levels should be monitored periodically — long-term use can cause deficiency. Generally well-tolerated and weight-neutral or weight-loss promoting.

HEPARIN MONITORING AND SAFETY is one of the most high-stakes pharmacology topics on the NCLEX. THERAPEUTIC aPTT RANGE: Typically 60-100 seconds (or 1.5-2.5 times the normal value of approximately 30-40 seconds); some institutions use anti-Xa levels instead. aPTT 140 SECONDS: This is well above the therapeutic range; risk of serious spontaneous bleeding is significantly elevated at this level; IMMEDIATE ACTIONS: (1) STOP THE HEPARIN INFUSION; (2) NOTIFY THE PROVIDER IMMEDIATELY; (3) ASSESS FOR BLEEDING: neurological changes (intracranial bleed); abdominal/back pain (retroperitoneal bleed); blood in urine, stool, vomit; decreased BP, tachycardia; unexplained bruising or bleeding from IV sites; (4) PREPARE FOR REVERSAL if ordered: PROTAMINE SULFATE is the specific antidote for heparin; dosing based on heparin units administered; given slowly IV (anaphylaxis risk — have resuscitation equipment ready); (5) REPEAT aPTT after interventions; (6) DOCUMENT. SUPRATHERAPEUTIC aPTT CAUSES: Too rapid an infusion rate; laboratory timing (drawn too soon after dose change); patient sensitivity; drug interactions. HEPARIN-INDUCED THROMBOCYTOPENIA (HIT): Monitor platelet count every 2-3 days; HIT is a paradoxical pro-coagulation reaction; platelets below 50% of baseline after starting heparin → stop heparin immediately.

INADEQUATE PAIN CONTROL requires systematic reassessment before any intervention. The nurse cannot simply give more opioid without assessment. COMPREHENSIVE REASSESSMENT: PAIN ASSESSMENT: Use a validated scale (NRS 0-10, Wong-Baker FACES, FLACC for non-verbal); Ask about location, quality (sharp, burning, aching, throbbing), intensity, radiation, duration, aggravating/relieving factors; Was the pain score accurate before the dose? Has it changed at all? VITAL SIGNS: Before administering more opioid, check respiratory rate, oxygen saturation, BP, HR; if respiratory rate below 12 or SpO₂ decreasing, do NOT give more opioid — call provider; REVIEW THE ORDER: What is the frequency? What is the dosage range (e.g., 2-4 mg)? When was the last dose? What are the parameters for holding or calling? POSSIBLE CAUSES OF INADEQUATE RELIEF: Under-dosing for the pain level; wrong route for the situation; inadequate drug for pain type (opioids work poorly for neuropathic pain — may need adjuvants); CONTACT PROVIDER: If pain remains uncontrolled after the assessment and another dose is clinically safe and ordered, notify provider with SBAR report: current pain score, vital signs, what was given, what the response has been, and request additional order. ADEQUATE PAIN CONTROL IS A PATIENT RIGHT — inadequate pain management should be escalated, not accepted as normal.

BETA-BLOCKER DISCONTINUATION SAFETY is the most critical education point for any patient taking a beta-blocker long-term. MECHANISM: Chronic beta-blockade causes upregulation of beta-adrenergic receptors (the body compensates by growing more receptors); abrupt discontinuation exposes these upregulated receptors to full catecholamine stimulation simultaneously; the result: sympathetic surge causing tachycardia, hypertension, and in patients with coronary artery disease, angina or MI. TEACHING POINTS: NEVER stop suddenly without medical guidance; if unable to take a dose, contact the provider; if a dose is missed, take it as soon as remembered unless close to the next dose time; store properly (some formulations need specific storage); SIDE EFFECTS TO MONITOR: Bradycardia — hold and call provider if pulse below 60 bpm; hypotension — rise slowly from sitting/lying; fatigue and exercise intolerance (common, often improves over time); impotence (beta-blockers affect sexual function); MASKING HYPOGLYCAEMIA: Beta-blockers blunt the tachycardia that normally warns diabetic patients of hypoglycaemia; diabetic patients must monitor blood glucose more carefully; OTHER EDUCATION: Take at the same time daily (Toprol-XL is extended release — do not crush or chew); do not use over-the-counter cold medications containing pseudoephedrine (sympathomimetic effect can counteract beta-blocker); avoid NSAIDS (reduce antihypertensive effect).

DKA MANAGEMENT requires a critical understanding of why insulin therapy continues even after blood glucose normalises. THE DKA PRINCIPLE: DKA is resolved when the anion gap normalises and ketones are cleared — NOT simply when blood glucose returns to normal. The insulin infusion is the treatment for the ketoacidosis, not just the hyperglycaemia. DEXTROSE ADDITION PROTOCOL: When blood glucose falls to 200-250 mg/dL (typical threshold), dextrose 5% or 10% is added to the maintenance IV fluid; this prevents hypoglycaemia while the insulin infusion continues at a reduced rate to resolve the ketoacidosis; the insulin must continue until the anion gap closes and bicarbonate normalises; WITHOUT dextrose addition: continuing insulin without dextrose when glucose reaches 200 mg/dL would cause hypoglycaemia before the acidosis is resolved; STOPPING INSULIN TOO EARLY: If insulin is stopped when glucose normalises but before ketosis resolves, the underlying metabolic problem is not treated and DKA will rebound. MONITORING PARAMETERS DURING DKA TREATMENT: Blood glucose every 1-2 hours; BMP every 2-4 hours (anion gap, bicarbonate, potassium, creatinine); strict I&O; vital signs every 1-4 hours; mental status; POTASSIUM REPLACEMENT: Critical — insulin drives potassium into cells, causing hypokalaemia; potassium must be checked before starting insulin; hold insulin if K+ below 3.5 mEq/L and replace first.

LITHIUM TOXICITY is a medical emergency requiring immediate intervention. The combination of supratherapeutic lithium level (1.4 mEq/L above the therapeutic range of 0.6-1.2) with SYMPTOMS of toxicity represents an urgent situation. LITHIUM TOXICITY PROGRESSION: EARLY (1.5-2.0 mEq/L): Fine-to-coarse hand tremor (progressing from the expected fine tremor at therapeutic levels); Nausea, vomiting, diarrhoea; Muscle weakness; MODERATE (2.0-2.5 mEq/L): Drowsiness, confusion, ataxia (unsteady gait); Slurred speech; Muscle twitching; Blurred vision; SEVERE (above 2.5 mEq/L): Seizures; Cardiac arrhythmias; Stupor/coma; Irreversible neurological damage; Death. WHY 1.4 IS CONCERNING: While 1.4 is only slightly above the therapeutic maximum, the SYMPTOMS indicate the patient's body is reacting adversely — symptoms at any level warrant evaluation; individual sensitivity varies; IMMEDIATE MANAGEMENT: HOLD lithium; emergency evaluation including repeat serum lithium level; fluid replacement (normal saline — dilutes lithium and promotes renal excretion); for severe toxicity: haemodialysis effectively removes lithium; PRECIPITATING FACTORS: Dehydration (vomiting, diarrhoea, excessive sweating, insufficient fluid intake); sodium restriction; NSAIDs (increase renal lithium retention); ACE inhibitors; thiazide diuretics. PATIENT EDUCATION: Maintain consistent fluid/sodium intake; report early symptoms; know when to seek emergency care; carry a medical alert identifier.

WARFARIN AND VITAMIN K INTERACTION is the most important dietary teaching for anticoagulated patients. MECHANISM: Warfarin works by blocking vitamin K-dependent clotting factors (II, VII, IX, X, Protein C and S); vitamin K in food COMPETES with warfarin's mechanism; more dietary vitamin K = lower anticoagulation effect (lower INR); less dietary vitamin K = higher anticoagulation effect (higher INR and bleeding risk). THE KEY TEACHING POINT — CONSISTENCY, NOT ELIMINATION: Patients do NOT need to avoid vitamin K foods completely; they should maintain a CONSISTENT amount from week to week; the warfarin dose is calibrated to their usual dietary intake; EXAMPLES OF HIGH-VITAMIN K FOODS: Leafy greens (spinach, kale, Swiss chard); Brussels sprouts; broccoli; cabbage; green tea; parsley; liver. SCENARIO: A patient on a stable warfarin dose decides to start a daily green smoothie with 2 cups of spinach — their vitamin K intake spikes → INR drops below therapeutic → thromboembolic event risk. Conversely, they stop eating greens during an illness → INR rises → bleeding risk. ADDITIONAL WARFARIN INTERACTIONS: DRUGS: Many drugs increase or decrease INR (antibiotics, antifungals, NSAIDs, aspirin, herbal supplements — especially St. John's Wort); ALCOHOL: Acute heavy alcohol use elevates INR; chronic alcohol use reduces it; ILLNESS AND DIET CHANGES: Any significant change in diet, illness, or new medication requires INR monitoring. PATIENT EDUCATION: Report any new medication (including OTC and herbal) to their provider; monitor for bleeding signs; know their target INR and what to do if they miss a dose.

WARFARIN (Coumadin) is monitored using PROTHROMBIN TIME (PT) and INR (international normalized ratio). NCLEX physiological/pharmacology. The therapeutic INR for most conditions is 2.0-3.0 (higher for some, e.g., mechanical heart valves). A too-high INR means increased bleeding risk; too-low means inadequate anticoagulation. The ANTIDOTE for warfarin is VITAMIN K. TEACHING: maintain consistent vitamin K intake (leafy greens) — don't suddenly change diet; watch for bleeding; many drug/food interactions. CONTRAST: HEPARIN is monitored with aPTT (activated partial thromboplastin time); its antidote is protamine sulfate. Knowing warfarin → PT/INR (vitamin K antidote) and heparin → aPTT (protamine antidote) is a heavily tested NCLEX pharmacology pairing.